XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Cash flows from operating activities:    
Net loss $ (105,980) $ (1,841)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 9,229 9,139
Stock-based compensation expense 7,692 7,327
Inventory impairments and abandonments 618 752
Deferred and other income tax expense (benefit) 112,752 (2,404)
Write-off of deposit on legacy land investment 0 2,700
Gain on sale of fixed assets (207) (123)
Change in allowance for doubtful accounts 62 (178)
Equity in income of unconsolidated entities (329) (233)
Cash distributions of income from unconsolidated entities 331 138
Non-cash loss on extinguishment of debt 3,173 3,676
Changes in operating assets and liabilities:    
Decrease in accounts receivable 8,256 13,588
Increase in income tax receivable (31) (88)
Increase in inventory (222,304) (70,770)
Increase in other assets (3,469) (1,970)
Increase in trade accounts payable 39,651 14,986
Increase (decrease) in other liabilities 17,080 (14,607)
Net cash used in operating activities (133,476) (39,908)
Cash flows from investing activities:    
Capital expenditures (13,894) (8,661)
Proceeds from sale of fixed assets 226 126
Investments in unconsolidated entities (421) (3,005)
Return of capital from unconsolidated entities 176 1,621
Net cash used in investing activities (13,913) (9,919)
Cash flows from financing activities:    
Repayment of debt (401,509) (257,173)
Proceeds from issuance of new debt 400,000 250,000
Repayment of borrowings from credit facility (75,000) (25,000)
Borrowings from credit facility 75,000 25,000
Debt issuance costs (5,743) (4,757)
Other financing activities (1,503) (403)
Net cash used in financing activities (8,755) (12,333)
Decrease in cash, cash equivalents, and restricted cash (156,144) (62,160)
Cash, cash equivalents, and restricted cash at beginning of period 304,609 243,276
Cash, cash equivalents, and restricted cash at end of period $ 148,465 $ 181,116